Chronic allograft dysfunction: A model disorder of innate immunity

Biomedical Journal

Volumn 36, Issue 5, 2013, Pages 209-228

  Land, Walter Gottlieb ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

allograft injuries; atherogenesis; chronic allograft dysfunction; damage associated molecular patterns; fibrogenesis; innate immunity

Indexed keywords

ABSENT IN MELANOMA 2; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CRYOPYRIN; CYCLOSPORIN A; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PATTERN RECOGNITION RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN DEATH; CHRONIC ALLOGRAFT DYSFUNCTION; CYTOKINE PRODUCTION; DAMAGE ASSOCIATED MOLECULAR PATTERN; DENDRITIC CELL; DYSLIPIDEMIA; FIBROGENESIS; FIBROSIS; GRAFT DYSFUNCTION; HUMAN; HYPERTENSION; IMMUNE MEDIATED INJURY; INFLAMMATION; INNATE IMMUNITY; KIDNEY FIBROSIS; MOLECULAR PATHOLOGY; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; REVIEW; TH17 CELL; TISSUE INJURY; VIRUS INFECTION;

ALLOGRAFTS; ANIMALS; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 84886382942     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.117622     Document Type: Review

References (218)

1. Land W. Allograft injury mediated by reactive oxygen species: From conserved proteins of Drosophila to acute and chronic rejection of human transplants. Part III: Interaction of (oxidative) stress-induced heat shock proteins with Toll-like receptor-bearing cells of innate immunity and its consequences for the development of acute and chronic allograft rejection. Transplant Rev 2003;17:67-86. (Pubitemid 36752624)
2. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005;79:505-14. (Pubitemid 40372243)
3. Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell 2010;140:771-6.
4. Racusen LC, Regele H. The pathology of chronic allograft dysfunction. Kidney Int Suppl 2010;119:S27-32.
5. Huibers M, De Jonge N, Van Kuik J, Koning ES, Van Wichen D, Dullens H, et al. Intimal fibrosis in human cardiac allograft vasculopathy. Transpl Immunol 2011;25:124-32.
6. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: The final frontier for lung transplantation. Chest 2011;140:502-8.
7. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994;57:211-7. (Pubitemid 24048587)
8. Land W, Messmer K. The impact of ischemia/reperfusion injury on specific and non-specific, early and late chronic events after organ transplantation. Transplant Rev 1996;10:108-27,236-53. (Pubitemid 126830410)
9. Land WG, Messmer K. The danger theory in view of the injury hypothesis: 20 years later. Front Immun 2012;3:349.
10. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045. (Pubitemid 24140436)
11. Matzinger P. The evolution of the danger theory. Interview by Lauren Constable, Commissioning Editor. Expert Rev Clin Immunol 2012;8:311-7.
12. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.
13. Xiang M, Fan J. Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol Med 2010;16:69-82.
14. Jounai N, Kobiyama K, Takeshita F, Ishii KJ. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol 2012;2:168.
15. Chen GY, Nuñez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010;10:826-37.
16. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011;108:235-48.
17. Land WG. Oxidative injury-induced, damage-associated molecular pattern molecules and their pattern recognition receptors. In Innate Alloimmunity. Part II. Innate Immunity and Rejection. In: Land WG, editor. Ankara, Lengerich: Bakent University-Pabst Science Publishers; 2011. p. 229-322.
18. Horvath GL, Schrum JE, De Nardo CM, Latz E. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol Rev 2011;243:119-35.
19. Bauernfeind F, Ablasser A, Bartok E, Kim S, Schmid-Burgk J, Cavlar T, et al. Inflammasomes: Current understanding and open questions. Cell Mol Life Sci 2011;68:765-83.
20. Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: Recent developments. Curr Opin Immunol 2013;25:40-5.
21. Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. Inflammasomes and host defenses against bacterial infections. Curr Opin Microbiol 2013;16:23-31.
22. Riteau N, Baron L, Villeret B, Guillou N, Savigny F, Ryffel B, et al. ATP release and purinergic signaling: A common pathway for particle-mediated inflammasome activation. Cell Death Dis 2012;3:e403.
23. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundbäck P, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012;488:670-4.
24. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012;36:401-14.
25. Haasken S, Sutterwala FS. Damage control: Management of cellular stress by the NLRP3 inflammasome. Eur J Immunol 2013;43;2003-5.
26. Rossol M, Pierer M, Raulien N, Quandt D, Meusch U, Rothe K, et al. Extracellular Ca (2+) is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun 2012;3:1329.
27. Compan V, Baroja-Mazo A, López-Castejón G, Gomez AI, Martínez CM, Angosto D, et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 2012;37:487-500.
28. Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009;31:5-22.
29. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204-12.
30. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045-51.
31. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: New insights and therapeutic approaches. J Clin Invest 2013;123:27-36.
32. Land WG. Interaction of damage-associated molecular patterns and pathogen-associated molecular patterns with pattern recognition receptor-bearing vascular cells and myofibroblasts and its consequences for the development of chronic allograft dysfunction. In Innate Alloimmunity. Part II. Innate Immunity and Rejection. In: Land WG, editor. Ankara, Lengerich: Bakent University-Pabst Science Publishers; 2011. p. 518-65.
33. Weismann D, Binder CJ. The innate immune response to products of phospholipid peroxidation. Biochim Biophys Acta 2012;1818:2465-75.
34. Zhang M, Carroll MC. Natural IgM-mediated innate autoimmunity: A new target for early intervention of ischemia-reperfusion injury. Expert Opin Biol Ther 2007;7:1575-82. (Pubitemid 47597144)
35. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004;22:361-403. (Pubitemid 38680427)
36. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest 2008;118:183-94.
37. Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein edeficient mice. Arterioscler Thromb Vasc Biol 2011;31:313-9.
38. Andrassy M, Volz HC, Schuessler A, Gitsioudis G, Hofmann N, Laohachewin D, et al. HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease. PLoS One 2012;7:e52081.
39. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 2006;20:2565-6.
40. Karagiannis GS, Weile J, Bader GD, Minta J. Integrative pathway dissection of molecular mechanisms of moxLDL-induced vascular smooth muscle phenotype transformation. BMC Cardiovasc Disord 2013;13:4.
41. Yu W, Liu-Bryan R, Stevens S, Damanahalli JK, Terkeltaub R. RAGE signalling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity. Atherosclerosis 2012;222:417-25.
42. González-Ramos M, Calleros L, López-Ongil S, Raoch V, Griera M, Rodríguez-Puyol M, et al. HSP70 increases extracellular matrix production by human vascular smooth muscle through TGF-1 up-regulation. Int J Biochem Cell Biol 2013;45:232-42.
43. Curtiss LK, Tobias PS. Emerging role of toll-like receptors in atherosclerosis. J Lipid Res 2009;50:5340-5.
44. Opitz B, Eitel J, Meixenberger K, Suttorp N. Role of Toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost 2009;102:1103-9.
45. Lundberg AM, Yan ZQ. Innate immune recognition receptors and damage-associated molecular patterns in plaque inflammation. Curr Opin Lipidol 2011;22:343-9.
46. Su X, Ao L, Shi Y, Johnson TR, Fullerton DA, Meng X. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J Biol Chem 2011;286:12213-20.
47. Mehta JL, Khaidakov M, Hermonat PL, Mitra S, Wang X, Novelli G, et al. LOX-1: A new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther 2011;25:495-500.
48. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011;106:858-67.
49. Tufano A, Di Capua M, Coppola A, Conca P, Cimino E, Cerbone AM, et al. The infectious burden in atherothrombosis. Semin Thromb Hemost 2012;38:515-23.
50. Yin Y, Pastrana JL, Li X, Huang X, Mallilankaraman K, Choi ET, et al. Inflammasomes: Sensors of metabolic stresses for vascular inflammation. Front Biosci 2013;18:638-49.
51. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
52. Rajamäki K, Lappalainen J, Oörni K, Välimäki E, Matikainen S, Kovanen PT, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS One 2010;5:e11765.
53. Masters SL, Latz E, O'Neill LA. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med 2011;3:81ps17.
54. Schlaweck S, Zimmer S, Struck R, Bartok E, Werner N, Bauernfeind F, et al. Critical role of nucleotide-binding oligomerization domain-like receptor 3 in vascular repair. Biochem Biophys Res Commun 2011;411:627-31.
55. Bauernfeind F, Bartok E, Rieger A, Franchi L, Núñez G, Hornung V. Cutting edge: Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 2011;187:613-7.
56. Jiang Y, Wang M, Huang K, Zhang Z, Shao N, Zhang Y, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1 by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun 2012;425:121-6.
57. Björkbacka H, Fredrikson GN, Nilsson J. Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis-A review of the experimental evidence. Atherosclerosis 2013;227:9-17.
58. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997;151:317-22.
59. Lee K, Nelson CM. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int Rev Cell Mol Biol 2012;294:171-221.
60. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
61. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116:217-24. (Pubitemid 36163863)
62. Nishimura SL. Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol 2009;175:1362-70.
63. Taylor AW. Review of the activation of TGF-beta in immunity. J Leukoc Biol 2009;85:29-33
64. Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, et al. Mitochondrial reactive oxygen species regulate transforming growth factor-signaling. J Biol Chem 2013;288:770-7.
65. Henderson NC, Sheppard D. Integrin-mediated regulation of TGF in fibrosis. Biochim Biophys Acta 2013;1832:891-6.
66. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-signaling in fibrosis. Growth Factors 2011;29:196-202.
67. Wynn TA, Barron L. Macrophages: Master regulators of inflammation and fibrosis. Semin Liver Dis 2010;30:245-57.
68. Lafyatis R, Farina A. New insights into the mechanisms of innate immune receptor signalling in fibrosis. Open Rheumatol J 2012;6:72-9.
69. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 2010;21:1299-308.
70. Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 2010;3:21.
71. Braga TT, Correa-Costa M, Guise YF, Castoldi A, de Oliveira CD, Hyane MI, et al. MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages. Mol Med 2012;8:1231-9.
72. Booth AJ, Wood SC, Cornett AM, Dreffs AA, Lu G, Muro AF, et al. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol 2012;226:609-18.
73. Hogaboam CM, Trujillo G, Martinez FJ. Aberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5 Suppl 1:S3.
74. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, et al. Toll-like receptor 4 signaling augments transforming growth factor-responses: A novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013;182:192-205.
75. Bai T, Lian LH, Wu YL, Wan Y, Nan Jx. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol 2013;15:275-81.
76. Kelly C, Canning P, Buchanan P, Williams MT, Brown VG, Gruenert DC, et al. Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2013;304:L371-82.
77. Englert JM, Kliment CR, Ramsgaard L, Milutinovic PS, Crum L, Tobolewski JM, et al. Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. Int J Clin Exp Pathol 2011;4:241-54.
78. Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J Gastroenterol 2011;17:4090-8.
79. Yin JP, Su ZL, Wang YM, Wang T, Tian SS, Xu XX, et al. Release of HMGB1 by LPS-treated cardiac fibroblasts and its contribution to the production of collagen type I and III. (English written abstract) Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012;28:785-8.
80. Lynch J, Nolan S, Slattery C, Feighery R, Ryan MP, McMorrow T. High-mobility group box protein 1: A novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol 2010;32:590-602.
81. Cai WF, Zhang XW, Yan HM, Ma YG, Wang XX, Yan J, et al. Intracellular or extracellular heat shock protein 70 differentially regulates cardiac remodelling in pressure overload mice. Cardiovasc Res 2010;88:140-9.
82. Sörensen I, Susnik N, Inhester T, Degen JL, Melk A, Haller H, et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 2011;80:1035-44.
83. Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010;2010. pii: 192543.
84. Duan X, Ponomareva L, Veeranki S, Panchanathan R, Dickerson E, Choubey D. Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res 2011;9:589-602.
85. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010;11:997-1004.
86. Bostanci N, Meier A, Guggenheim B, Belibasakis GN. Regulation of NLRP3 and AIM2 inflammasome gene expression levels in gingival fibroblasts by oral biofilms. Cell Immunol 2011;270:88-93.
87. Artlett CM. The Role of the NLRP3 Inflammasome in Fibrosis Open Rheumatol J 2012;6:80-6.
88. Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 2011;63:3563-74.
89. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011;123:594-604.
90. Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, et al. Inflammasome-independent NLRP3 augments TGF-signaling in kidney epithelium. J Immunol 2013;190:1239-49.
91. Chaudhuri V, Zhou L, Karasek M. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: A potential role in skin fibrogenesis. J Cutan Pathol 2007;34:146-53. (Pubitemid 46145554)
92. Fix C, Bingham K, Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 2011;53:19-28.
93. Postlethwaite AE, Raghow R, Stricklin GP, Poppleton H, Seyer JM, Kang AH. Modulation of fibroblast functions by interleukin 1: Increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 1988;106:311-8. (Pubitemid 18052181)
94. Gasse P, Riteau N, Charron S, Girre S, Fick L, Pétrilli V, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009;179:903-13.
95. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 2010;182:774-83.
96. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010;207:535-52.
97. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, di Padova F, et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 2011;6:e23185.
98. Dong Z, Kang Q, Lei W, Zhong H, Tai W, Wang D. Effects of interleukin-17 on murine pulmonary fibroblast proliferation, transformation and collagen synthesis (English written abstract). Nan Fang Yi Ke Da Xue Xue Bao 2012;32:75-9.
99. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 2012;64:3726-35.
100. Aoki H, Ohnishi H, Hama K, Ishijima T, Satoh Y, Hanatsuka K, et al. Autocrine loop between TGF-beta1 and IL-1beta through Smad3-and ERK-dependent pathways in rat pancreatic stellate cells. Am J Physiol Cell Physiol 2006;290:C1100-8.
101. Markovics JA, Araya J, Cambier S, Somanath S, Gline S, Jablons D, et al. Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture. J Biol Chem 2011;286:36864-74.
102. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin v8-mediated activation of TGF-. J Clin Invest 2011;121:2863-75.
103. Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differentiation and expansion of IL-17A-and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol 2010;184:7268-80.
104. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vf9Vr2 T cells. Blood 2011;118:129-38.
105. Mills KH, Dungan LS, Jones SA, Harris J. The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 2013;93:489-97.
106. Peral de Castro C, Jones SA, Ní Cheallaigh C, Hearnden CA, Williams L, Winter J, et al. Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. J Immunol 2012;189:4144-53.
107. Sutton CE, Mielke LA, Mills KH. IL-17-producing T cells and innate lymphoid cells. Eur J Immunol 2012;42:2221-31.
108. Havenar-Daughton C, Li S, Benlagha K, Marie JC. Development and function of murine RORt+iNKT cells are under TGF-signaling control. Blood 2012;119:3486-94.
109. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells. Cell 2006;126:1121-33. (Pubitemid 44380299)
110. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gamma delta T Cells, amplifying Th17 responses and autoimmunity. Immunity 2009;31:331-41.
111. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
112. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: Biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012;181:8-18.
113. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 2006;441:231-4.
114. Li MO, Flavell RA. TGF-beta: A master of all T cell trades. Cell 2008;134:392-404.
115. Manel N, Unutmaz D, Littman DR. The differentiation of human T (H)-17 cells requires transforming growth factor-and induction of the nuclear receptor RORt. Nat Immunol 2008;9:641-9. (Pubitemid 351714729)
116. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, et al. A critical function for transforming growth factor-, interleukin 23 and proinflammatory cytokines in driving and modulating human T (H)-17 responses. Nat Immunol 2008;9:650-7. (Pubitemid 351712635)
117. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
118. Huang G, Wang Y, Chi H. Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol 2012;9:287-95.
119. Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. Autocrine transforming growth factor-1 promotes in vivo Th17 cell differentiation. Immunity 2011;34:396-408.
120. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006;203:1685-91. (Pubitemid 44036274)
121. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, et al. Pathogen-induced human TH17 cells produce IFN-or IL-10 and are regulated by IL-1. Nature 2012;484:514-8.
122. Jones SA, Mills KH, Harris J. Autophagy and inflammatory diseases. Immunol Cell Biol 2013;91:250-8.
123. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-9.
124. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, et al. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol 2001;25:474-85. (Pubitemid 33037680)
125. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126-47. (Pubitemid 30158482)
126. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10:464-71.
127. Topilsky Y, Gandhi MJ, Hasin T, Voit LL, Raichlin E, Boilson BA, et al. Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy-a three-dimensional volumetric intravascular ultrasound study. Transplantation 2013;95:389-96.
128. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008;8:753-60. (Pubitemid 351347767)
129. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant 2013;13:634-44.
130. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: The final frontier for lung transplantation. Chest 2011;140:502-8.
131. Land WG. Oxidative allograft injury and other acute and chronic risk factors for the development of chronic allograft dysfunction-revisited in light of innate immunity. In Innate Alloimmunity. Part II. Innate Immunity and Rejection. In: Land WG, editor. Ankara, Lengerich: Bakent University-Pabst Science Publishers; 2011. p. 566-86.
132. Pratschke J, Wilhelm MJ, Laskowski I, Kusaka M, Beato F, Tullius SG, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001;12:2474-81. (Pubitemid 33021126)
133. Kosieradzki M, Kuczynska J, Piwowarska J, Wegrowicz-Rebandel I, Kwiatkowski A, Lisik W, et al. Prognostic significance of free radicals: Mediated injury occurring in the kidney donor. Transplantation 2003;75:1221-7. (Pubitemid 36513024)
134. Leber B, Stadlbauer V, Stiegler P, Stanzer S, Mayrhauser U, Koestenbauer S, et al. Effect of oxidative stress and endotoxin on human serum albumin in brain-dead organ donors. Transl Res 2012;159:487-96.
135. Arbogast H, Arbogast S, Fertmann J, Abendroth D, Illner WD, Land W, et al. Expression of heat shock proteins in cadaveric human renal allografts-a role in activation of innate immunity Transplantation 2002;74:266.
136. Krüger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009;106:3390-5.
137. Quiroga I, Salio M, Koo DD, Cerundolo L, Shepherd D, Cerundolo V, et al. Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006;81:1196-203.
138. Rostron AJ, Cork DM, Avlonitis VS, Fisher AJ, Dark JH, Kirby JA. Contribution of Toll-like receptor activation to lung damage after donor brain death. Transplantation 2010;90:732-9.
139. Chen L, Xu D, Gao Y, Cui X, Du Z, Ding Q, et al. Effect of donor JNK signal transduction inhibition on transplant outcome in brain dead rat model. Inflammation 2012;35:122-9.
140. Damman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, Seelen MA. Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant 2011;11:660-9.
141. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998;65:1533-42. (Pubitemid 28304585)
142. Kusaka M, Pratschke J, Wilhelm MJ, Ziai F, Zandi-Nejad K, Mackenzie HS, et al. Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation 2000;69:405-1.
143. Danobeitia JS, Sperger JM, Hanson MS, Park EE, Chlebeck PJ, Roenneburg DA, et al. Early activation of the inflammatory response in the liver of brain-dead non-human primates. J Surg Res 2012;176:639-48.
144. Morariu AM, Martins PN, Leuvenink HG. Brain death and donor age synergistically accelerate the early immune response of allograft recipient (abstract# 0155). Transpl Int 2007;20:47.
145. Velásquez-Lopera MM, Correa LA, García LF. Human spleen contains different subsets of dendritic cells and regulatory T lymphocytes. Clin Exp Immunol 2008;154:107-14.
146. Pratschke J, Wilhelm MJ, Laskowski I, Kusaka M, Beato F, Tullius SG, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001;12:2474-81. (Pubitemid 33021126)
147. Fertmann J, Arbogast H, Hoffmann J, Land W. Generation of hydroxyl radical is increased after reperfusion of human cadaveric renal allografts. Transplantation 2002;74:393.
148. Land WG. Emerging role of innate immunity in organ transplantation: Part I: Evolution of innate immunity and oxidative allograft injury. Transplant Rev (Orlando) 2012;26:60-72.
149. de Vries DK, Schaapherder AF, Reinders ME. Mesenchymal stromal cells in renal ischemia/reperfusion injury. Front Immunol 2012;3:162.
150. Furukawa Y, Libby P, Stinn JL, Becker G, Mitchell RN. Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. Am J Pathol 2002;160:1077-87. (Pubitemid 34224594)
151. Kaczorowski DJ, Tsung A, Billiar TR. Innate immune mechanisms in ischemia/reperfusion. Front Biosci 2009;1:91-8.
152. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol 2013;10:79-89.
153. Iyer S, Pulskensc W, Sadler J, Butter LM, Teske GJ, Ulland TK, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. PNAS 2009;106:20388-93.
154. Land WG. Emerging role of innate immunity in organ transplantation part II: Potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transplant Rev (Orlando) 2012;26:73-87.
155. Halloran PF, de Freitas DG, Einecke G, Famulski KS, Hidalgo LG, MengeL M, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010;10:2223-30.
156. Matignon M, Muthukumar T, Seshan SV, Suthanthiran M, Hartono C. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation 2012;94:603-11.
157. Sun K, Kiss E, Bedke J, Stojanovic T, Li Y, Gwinner W, et al. Role of xanthine oxidoreductase in experimental acute renal-allograft rejection. Transplantation 2004;77:1683-92. (Pubitemid 38780534)
158. Ott U, Aschoff A, Funfstuck R, Jirikowski G, Wolf G. DNA fragmentation in acute and chronic rejection after renal transplantation. Transplant Proc 2007;39:73-7. (Pubitemid 46175944)
159. Bhandary UV, Shirodkar B, Tse W, Hodgkinson AD, Demaine AG. A polymorphism of NADPH oxidase p22 phox is associated with reduced susceptibility to acute rejection in renal allograft recipients. Transpl Immunol 2011;25:16-9.
160. Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: A schematic view based on pathogenesis. Transplantation 2013;95:1073-83.
161. Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013;32:70-7.
162. Loverre A, Tataranni T, Castellano G, Divella C, Battaglia M, Ditonno P, et al. IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibody-mediated rejection. Am J Transplant 2011;11:1248-59.
163. Abadja F, Sarraj B, Ansari MJ. Significance of T helper 17 immunity in transplantation. Curr Opin Organ Transplant 2012;17:8-14.
164. Zhang Q, Reed EF. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010;22:682-8.
165. Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q. Anti-heat shock
166. Moser B, Szabolcs MJ, Ankersmit HJ, Lu Y, Qu W, Weinberg A, et al. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant 2007;7:293-302. (Pubitemid 46096322)
167. Pockley AG, Muthana M. Heat shock proteins and allograft rejection. Contrib Nephrol 2005;148:122-34. (Pubitemid 43264926)
168. Wang S, Schmaderer C, Kiss E, Schmidt C, Bonrouhi M, Porubsky S, et al. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88-and TRIF-dependent signaling. Dis Model Mech 2010;3:92-103.
169. Wei W, Chen M, Zhu Y, Wang J, Zhu P, Li Y, et al. Down-regulation of vascular HMGB1 and RAGE expression by n-3 polyunsaturated fatty acids is accompanied by amelioration of chronic vasculopathy of small bowel allografts. J Nutr Biochem 2012;23:1333-40.
170. Kis-Toth K, Szanto A, Thai TH, Tsokos GC. Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response. J Immunol 2011;187:1222-34.
171. Seto T, Kamijo S, Wada Y, Yamaura K, Takahashi K, Komatsu K, et al. Upregulation of the apoptosis-related inflammasome in cardiac allograft rejection. J Heart Lung Transplant 2010;29:352-9.
172. Duan L, Wang CY, Chen J, Gong Q, Zhu P, Zheng F, et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab Invest 2011;91:43-53.
173. Rao DA, Pober JS. Endothelial injury, alarmins, and allograft rejection. Crit Rev Immunol 2008;28:229-48.
174. Yin Y, Pastrana JL, Li X, Huang X, Mallilankaraman K, Choi ET, et al. Inflammasomes: Sensors of metabolic stresses for vascular inflammation. Front Biosci 2013;18:638-49.
175. Grebe A, Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep 2013;15:313.
176. Keller MR, Burlingham WJ. Loss of tolerance to self after transplant. Semin Immunopathol 2011;33:105-10.
177. Chung BH, Kim KW, Kim BM, Piao SG, Lim SW, Choi BS, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. PLoS One 2012;7:e42011.
178. Mitsdoerffer M, Lee Y, Jager A, Kim HJ, Korn T, Kolls JK, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Nat Acad Sci USA 2010;107:14292-7.
179. He Z, Shotorbani SS, Jiao Z, Su Z, Tong J, Liu Y, et al. HMGB1 promotes the differentiation of Th17 via up-regulating TLR2 and IL-23 of CD14+ monocytes from patients with rheumatoid arthritis. Scand J Immunol 2012;76:483-9.
180. Wilson JM, Kurtz CC, Black SG, Ross WG, Alam MS, Linden J, et al. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. J Immunol 2011;186:6746-52.
181. Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998;101:398-405. (Pubitemid 28067337)
182. Nath DS, Tiriveedhi V, Basha HI, Phelan D, Moazami N, Ewald GA, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011;91:1036-43.
183. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension 2011;57:132-40.
184. Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 2009;11:1651-67.
185. Ando J, Yamamoto K. Effects of shear stress and stretch on endothelial function. Antioxid Redox Signal 2011;15:1389-403.
186. Schiffrin EL. The Immune System: Role in Hypertension. Can J Cardiol 2013;29:543-8.
187. Ding N, Wang F, Han Y, Xiao H, Xu L, She S. Mitogen-activated protein kinase kinase 6 mediates mechanical stretch-induced high-mobility group box 1 protein expression in pulmonary alveolar epithelial cells. J Trauma Acute Care Surg 2012;72:162-8.
188. Inoue N, Kawashima S, Hirata KI, Rikitake Y, Takeshita S, Yamochi W, et al. Stretch force on vascular smooth muscle cells enhances oxidation of LDL via superoxide production. Am J Physiol 1998;274:H1928-32.
189. Luo SS, Sugimoto K, Fujii S, Takemasa T, Fu SB, Yamashita K. Role of heat shock protein 70 in induction of stress fiber formation in rat arterial endothelial cells in response to stretch stress. Acta Histochem Cytochem 2007;40:9-17. (Pubitemid 46356014)
190. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, et al. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension Am J Med Sci 2012;343:46-51.
191. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, et al. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med 2013;18:1509-18.
192. Dunzendorfer S, Lee HK, Tobias PS. Flow-dependent regulation of endothelial Toll-like receptor 2 expression through inhibition of SP1 activity. Circ Res 2004;95:684-91. (Pubitemid 39331928)
193. Li BH, Zhang LL, Pi Y, Yin YW, Yang QW, Fang CQ, et al. Role of toll like receptor 4 in low shear stress-induced intimal hyperplasia (English written abstract). Zhonghua Yi Xue Za Zhi 2012;92:773-7.
194. Li Y, Liu S, Zhang Z, Xu Q, Xie F, Wang J, et al. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation. PLoS One 2012;7:e35016.
195. DeVerse JS, Bailey KA, Jackson KN, Passerini AG. Shear stress modulates RAGE-mediated inflammation in a model of diabetes-induced metabolic stress. Am J Physiol Heart Circ Physiol 2012;302:H2498-508.
196. Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011;7:11-21.
197. Azibani F, Fazal L, Chatziantoniou C, Samuel JL, Delcayre C. Hypertension-induced fibrosis: A balance story. Ann Cardiol Angeiol (Paris) 2012;61:150-5.
198. Skogstrand T, Leh S, Paliege A, Reed RK, Vikse BE, Bachmann S, et al. Arterial damage precedes the development of interstitial damage in the nonclipped kidney of two-kidney, one-clip hypertensive rats. J Hypertens 2013;31:152-9.
199. Palm F, Nordquist L. Renal oxidative stress, oxygenation, and hypertension. Am J Physiol Regul Integr Comp Physiol 2011;301:R1229-41.
200. Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: Diagnosis and treatment. Curr Diab Rep 2009;9:305-11.
201. Land WG. Aging and immunosuppression in kidney transplantation. Exp Clin Transplant 2004;2:229-37.
202. Rezzani R. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: The morphological and immunohistochemical studies. Histol Histopathol 2006;21:301-16. (Pubitemid 43033739)
203. Keane T, Egan D, Ryan MP. Signalling pathways involved in cyclosporine A-induced TGF-1 secretion from a renal tubular epithelial cell line. J Am Soc Nephrol 1998;9:A3045.
204. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2005;20:2215-25. (Pubitemid 41510100)
205. Lim SW, Li C, Ahn KO, Kim J, Moon IS, Ahn C, et al . Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells. Transplantation 2005;80:691-9. (Pubitemid 41379412)
206. Ghee JY, Han DH, Song HK, Kim WY, Kim SH, Yoon HE, et al. The role of macrophage in the pathogenesis of chronic cyclosporine-induced nephropathy. Nephrol Dial Transplant 2008;23:4061-9.
207. Yoon HE, Yang CW. Established and newly proposed mechanisms of chronic cyclosporine nephropathy. Korean J Intern Med 2009;24:81-92.
208. Dupont PJ, Manuel O, Pascual M. Infection and chronic allograft dysfunction. Kidney Int Suppl 2010;119:S47-53.
209. Ribeiro A, Wörnle M, Motamedi N, Anders HJ, Gröne EF, Nitschko H, et al. Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy. Kidney Int 2012;81:100-11.
210. Hirsch HH, Randhawa P; the AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant 2013;13:179-88.
211. Erridge C. The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med 2008;18:52-6. (Pubitemid 351282493)
212. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011;106:858-67.
213. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004;4:169-77. (Pubitemid 38248518)
214. Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007;19:577-82. (Pubitemid 47464920)
215. Dzabic M, Rahbar A, Yaiw KC, Naghibi M, Religa P, Fellström B, et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011;53:969-76.
216. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system Nat Rev Immunol 2013;13:176-89.
217. Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2013;33:S43-9.
218. Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J Clin Immunol 2013;33:62-6.